Investing in Johnson & Johnson

Johnson & Johnson has been a part of people's lives for 127 years and a valuable part of their investments for more than 65 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 29 consecutive years of adjusted earnings increases; and 51 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 5.5 percent total return for investors compared to a 7.1 percent total return for the S&P 500.⁽¹⁾

E-Delivery of Annual Meeting and Proxy Materials

Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.

Click here for the on-line Annual Report Click here for the Proxy Statement

You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.

Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to www.computershare-na.com/green or contact our transfer agent, Computershare, at 1-800-328-9033.

Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.

Investor News

May 21, 2013
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

May 20, 2013
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Including ZYTIGA^®, Ibrutinib and Daratumumab Data

May 15, 2013
SIMPONI^® (Golimumab) Receives FDA Approval For Ulcerative Colitis

Investor Communications

May 23, 2013 at 8:30 AM ET
Johnson & Johnson Pharmaceuticals Business Review

April 16, 2013 at 8:30 AM ET
Johnson & Johnson First Quarter 2013 Earnings Meeting and Webcast

Financial Quick Links

Johnson & Johnson Reports 2013 First-Quarter Results

Supplemental Sales Data Q1 2013

Reconciliation of Non-GAAP Financial Measures Q1 2013

5 Year Financial Review

1. Data source - Bloomberg